Please login to the form below
metreleptin
This page shows the latest metreleptin news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar and Xeljanz
Aegerion’s rare disease drug approved. Specialist pharma company Aegerion has gained European approval for Myalepta (metreleptin) for the ultra-rare condition, lipodystrophy.
Latest news
-
Daily Brief: ASCO latest, Europe cautions on immunotherapy, rejects Duchenne treatment
Another orphan drug, Novelion’s Myalepta (metreleptin) also received a positive opinion, for the treatment of leptin deficiency, while Lundbeck and Otsuka’s Rxulti (brexpiprazole) was recommended for the treatment of
-
R&D productivity takes off
For example, Amgen's Blincyto (blinatumomab) for a rare form of leukaemia has been priced at $178, 000 a year, while AZ's Myalept (metreleptin) for the ultra-rare metabolic disorder
-
Nexium windfall lifts AZ in third quarter
Meanwhile, AZ also said it is selling Myalept (metreleptin), an approved drug for generalised lipodystrophy, to Aegerion Pharmaceuticals.
-
FDA approves AZ’s fish oil drug
Epanova gets green light to reduce high levels of fat in the blood
-
AZ gets limited approval for metreleptin in US
Myalept (metreleptin) - a recombinant form of the hormone leptin that was unsuccessfully studied as an obesity therapy by Bristol-Myers Squibb (BMS) - has been approved as a replacement therapy for patients ... The company stressed that metreleptin is
More from news
Approximately 3 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Deal Watch table for November 2014
Option. 444. AstraZeneca / Aegerion. Myalet (metreleptin) injection for leptin deficiency.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Medical Editor
-
Competitive Salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Associate Account Director
-
Competitive Salary
-
Senior Medical Writer
-
Competitive Salary
-
Account Management
-
Competitive Salary Offered
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
-
Publications Director
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
-
Account Manager
-
Competitive Salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Senior Account Executive
-
Competitive Salary
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- Merck & Co reveals plans for women’s health spinoff Organon
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- bluebird bio aiming to separate business units by year-end
- AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER
- Sharing patient stories for World Pulmonary Hypertension Day
- AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- China’s Sinopharm given WHO emergency use listing for COVID-19 vaccine
- Pfizer, BioNTech file for full US approval of COVID-19 vaccine
- The impact of cancer on mental health during COVID-19
- Single dose of COVID-19 vaccines ‘significantly’ reduces infections
- US states claim Purdue Pharma owes $2.2 trillion over opioid crisis
- The new reality of building a corporate brand in pharma
- FDA approves expanded use for Chiesi’s sickle cell drug Ferriprox
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- Lilly’s RET inhibitor Retevmo shows early promise in new cancer types
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- Sharing patient stories for World Pulmonary Hypertension Day
- For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
- How nature can help you manage the pressures of agency life
- Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
- How can we strike the right balance between familiarity and innovation when it comes to data presentation?
- Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
